PriceTargets.com logo

Elanco Animal Health - ELAN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $16.50
  • Forecasted Upside: 78.96%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.22 As of 06/2/2023 05:32 PM ET
▲ +0.62 (7.21%)

This chart shows the closing price for ELAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elanco Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELAN

Analyst Price Target is $16.50
▲ +78.96% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $16.50, with a high forecast of $22.00 and a low forecast of $12.00. The average price target represents a 78.96% upside from the last price of $9.22.

This chart shows the closing price for ELAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Elanco Animal Health. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
3/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2023BarclaysUpgradeEqual Weight ➝ Overweight$14.00Low
3/2/2023Piper SandlerLower Target$15.00 ➝ $12.00Low
2/22/2023BarclaysLower TargetEqual Weight$18.00 ➝ $14.00Low
1/30/2023Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00Low
11/15/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00Low
11/14/2022Piper SandlerLower TargetNeutral$21.00 ➝ $15.00Low
11/9/2022The Goldman Sachs GroupLower TargetSell$19.00 ➝ $12.00Low
11/8/2022William BlairReiterated RatingMarket PerformLow
10/17/2022JPMorgan Chase & Co.Lower TargetNeutral$24.00 ➝ $20.00Low
10/7/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $21.00Low
9/12/2022BarclaysLower TargetEqual Weight$32.00 ➝ $18.00Low
8/18/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$37.00 ➝ $22.00Low
8/16/2022Piper SandlerLower TargetNeutral$22.00 ➝ $21.00Low
8/16/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $24.00Low
7/21/2022The Goldman Sachs GroupDowngradeBuy ➝ Sell$32.00 ➝ $19.00Low
7/11/2022Piper SandlerInitiated CoverageNeutral$22.00N/A
6/24/2022Stifel NicolausLower TargetHold$30.00 ➝ $22.00Low
5/19/2022The Goldman Sachs GroupLower TargetBuy$37.00 ➝ $32.00Low
5/17/2022Morgan StanleyLower TargetOverweight$37.00Low
2/28/2022BarclaysBoost TargetEqual Weight$30.00 ➝ $32.00Low
12/8/2021BarclaysReiterated RatingNeutral ➝ HoldHigh
11/18/2021Morgan StanleyInitiated CoverageOverweight$40.00Medium
10/28/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $34.00Medium
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$38.00High
5/17/2021CitigroupReiterated RatingBuy$39.00 ➝ $42.00High
5/11/2021G.ResearchUpgradeHold ➝ BuyLow
5/11/2021GabelliUpgradeHold ➝ BuyMedium
5/11/2021BarclaysUpgradeUnderweight ➝ Equal Weight$25.00 ➝ $29.00Medium
4/20/2021Stifel NicolausInitiated CoverageBuy$37.00N/A
4/14/2021Stifel NicolausInitiated CoverageBuy$37.00Low
3/29/2021GabelliReiterated RatingBuy ➝ Hold$32.00High
3/22/2021GabelliDowngradeBuy ➝ Hold$32.00High
3/22/2021Raymond JamesReiterated RatingHoldHigh
3/8/2021CitigroupBoost Target$35.00 ➝ $39.00Low
2/26/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$33.00 ➝ $38.00High
12/9/2020ArgusDowngradeBuy ➝ HoldMedium
11/23/2020Morgan StanleyBoost TargetOverweight$31.00 ➝ $41.00High
11/9/2020BarclaysDowngradeOverweight ➝ Underweight$35.00 ➝ $25.00High
10/26/2020BarclaysBoost TargetOverweight$25.00 ➝ $35.00Medium
10/7/2020Raymond JamesReiterated RatingHoldMedium
10/1/2020CitigroupBoost TargetBuy$27.00 ➝ $32.00Medium
9/28/2020Raymond JamesReiterated RatingHoldLow
8/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$24.00 ➝ $31.00High
8/18/2020ArgusBoost TargetPositive ➝ Buy$26.00 ➝ $30.00Low
8/12/2020Credit Suisse GroupInitiated CoverageNeutral$27.00Medium
8/4/2020The Goldman Sachs GroupInitiated CoverageBuy$26.50High
7/20/2020Bank of AmericaBoost TargetBuy$26.00 ➝ $28.00Low
5/15/2020CitigroupLower TargetBuy$35.00 ➝ $27.00Medium
5/13/2020BarclaysReiterated RatingBuy$25.00Medium
4/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
3/25/2020Credit Suisse GroupReiterated RatingBuyHigh
1/14/2020GabelliReiterated RatingBuyHigh
1/9/2020Raymond JamesInitiated CoverageMarket PerformHigh
12/19/2019Bank of AmericaUpgradeNeutral ➝ Buy$34.00High
11/20/2019UBS GroupLower TargetNeutral$30.00 ➝ $28.00Low
11/7/2019Morgan StanleyUpgradeEqual ➝ Equal Weight$34.00 ➝ $32.00Medium
9/23/2019BarclaysInitiated CoverageOverweight$36.00Medium
9/9/2019The Goldman Sachs GroupInitiated CoveragePositiveMedium
8/26/2019Bank of AmericaDowngradeBuy ➝ Neutral$30.00Low
8/15/2019UBS GroupUpgradeSell ➝ Neutral$31.00 ➝ $30.00Medium
5/22/2019GuggenheimInitiated CoverageNeutral ➝ NeutralLow
5/10/2019BMO Capital MarketsBoost TargetMarket Perform$32.00 ➝ $35.00Low
3/20/2019UBS GroupInitiated CoverageSell$29.00 ➝ $28.00Low
3/18/2019Bank of AmericaUpgradeNeutral ➝ Buy$30.95Low
3/13/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$34.00Low
2/11/2019William BlairInitiated CoverageMkt Perform ➝ Market Perform$29.71Medium
1/23/2019UBS GroupInitiated CoverageSell ➝ Sell$29.00High
1/15/2019ArgusInitiated CoverageBuy$37.00Low
1/4/2019Credit Suisse GroupReiterated RatingHold$33.00Low
12/19/2018BMO Capital MarketsLower TargetMarket Perform$37.00 ➝ $32.00High
12/17/2018Credit Suisse GroupReiterated RatingHold$36.00High
11/13/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$33.00 ➝ $37.00Low
10/15/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$36.00High
10/15/2018CitigroupInitiated CoverageBuy ➝ Buy$37.00High
10/15/2018CowenInitiated CoverageOutperformLow
10/15/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$34.00Low
10/15/2018Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$35.00Low
10/15/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$38.00Low
10/15/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$30.00Low
10/12/2018Craig HallumInitiated CoverageHoldLow
9/26/2018BMO Capital MarketsInitiated CoverageMarket Perform$33.00High
9/19/2018GabelliInitiated CoverageBuy ➝ Buy$32.00N/A
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2023
  • 17 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/2/2023
  • 23 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 15 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 18 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2023
  • 12 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 12 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Elanco Animal Health logo
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants &
Read More

Today's Range

Now: $9.22
Low: $8.75
High: $9.23

50 Day Range

MA: $9.04
Low: $8.09
High: $10.17

52 Week Range

Now: $9.22
Low: $7.88
High: $24.88

Volume

9,419,723 shs

Average Volume

7,842,242 shs

Market Capitalization

$4.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Elanco Animal Health?

The following sell-side analysts have issued research reports on Elanco Animal Health in the last twelve months: Barclays PLC, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, and William Blair.
View the latest analyst ratings for ELAN.

What is the current price target for Elanco Animal Health?

6 Wall Street analysts have set twelve-month price targets for Elanco Animal Health in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 91.6%. Stifel Nicolaus has the highest price target set, predicting ELAN will reach $22.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $12.00 for Elanco Animal Health in the next year.
View the latest price targets for ELAN.

What is the current consensus analyst rating for Elanco Animal Health?

Elanco Animal Health currently has 1 sell rating, 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ELAN, but not buy more shares or sell existing shares.
View the latest ratings for ELAN.

What other companies compete with Elanco Animal Health?

Other companies that are similar to Elanco Animal Health include TG Therapeutics, Perrigo, ACADIA Pharmaceuticals, Arrowhead Pharmaceuticals and Cytokinetics. Learn More about companies similar to Elanco Animal Health.

How do I contact Elanco Animal Health's investor relations team?

Elanco Animal Health's physical mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company's listed phone number is (877) 352-6261 and its investor relations email address is kanaga_tiffa[email protected]. The official website for Elanco Animal Health is www.elanco.com. Learn More about contacing Elanco Animal Health investor relations.